CA Patent

CA3039745A1 — Pharmaceutical composition, methods for treating and uses thereof

Assigned to Boehringer Ingelheim International GmbH · Expires 2018-05-17 · 8y expired

What this patent protects

The present invention relates to methods for treating or preventing chronic kidney disease and cardiovascular disease in patients with chronic kidney disease comprising administering empagliflozin to the patient.

USPTO Abstract

The present invention relates to methods for treating or preventing chronic kidney disease and cardiovascular disease in patients with chronic kidney disease comprising administering empagliflozin to the patient.

Drugs covered by this patent

Patent Metadata

Patent number
CA3039745A1
Jurisdiction
CA
Classification
—
Expires
2018-05-17
Drug substance claim
No
Drug product claim
No
Assignee
Boehringer Ingelheim International GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.